[ad_1]

  • New data supports the feasibility of machine learning algorithms to detect elevated left ventricular end-diastolic pressure (LVEDP)

  • Data collected using CorVista System®. It is the world’s first non-invasive point-of-care solution approved to assess the presence of coronary artery disease and pulmonary hypertension.

Bethesda, Maryland, April 7, 2024–(BUSINESS WIRE)–CorVista Health, Inc., a leading digital health company focused on improving the diagnosis of cardiovascular disease, releases new data exploring the potential of non-invasive point-of-care rule-out testing for heart failure To do. Using Machine Learning at the American College of Cardiology 73rd Annual Scientific Sessions and Exposition in Atlanta, Georgia on April 7th.

The CorVista System is the world’s first non-invasive point-of-care solution for assessing the presence of coronary artery disease and pulmonary hypertension. The developed model presented aims to assess left ventricular end-diastolic pressure (LVEDP) as an effective exclusion test, with a sensitivity of 92% (≥25 mmHg) and 86% (≥20 mmHg). Shows potential to work. mmHg), specificity was 68% (TTE group), negative predictive value was 99.5% (≥25mmHg) and 99.1% (≥20mmHg), and prevalence was 4%.

Timely identification of left ventricular dysfunction plays a crucial role in effective heart failure management, but measurement of LVEDP elevation currently relies on invasive left heart catheterization. Echocardiographic indicators can be used to indicate possible diastolic dysfunction, but challenges exist in data collection and interpretation, and the use of non-invasive point-of-care methods to identify patients with elevated LVEDP. The need has arisen.

“This data powers CorVista’s new machine learning diagnostic solution to identify patients with CAD (coronary artery disease), PH (pulmonary hypertension) (both currently FDA cleared), and elevated LVEDP at the point of care. Elevated PH and LVEDP are both significantly unrecognized and underdiagnosed, especially when caused by heart failure with preserved ejection fraction (HFpEF), and therefore require life-saving treatment. is often delayed,” said Charles Bridges, MD, executive vice president and chief scientific officer. CorVista Health. “We believe the CorVista system uniquely and effectively addresses the important unmet needs of people living with cardiovascular disease, especially in rural and underserved populations. .”

main author

summary title

Presentation details

Navid Nemati

Non-invasive development

Point-of-care rule-out test

Heart failure using machine learning

Session 1462 – Innovation, Digital

HEALTH AND TECHNOLOGY 14

April 7, 2024 – 3:15 PM ET

Location: Hall B4-5

(Georgia World Congress Center)

About the CorVista® System

The CorVista system is an Rx-only, non-invasive, point-of-care solution that synchronously collects cardiac and hemodynamic signals from symptomatic patients and applies machine learning to detect radiological, contrast, and cardiovascular disease potential. The purpose is to predict gender. injections, fasting, or exercise. Within minutes of the test, CorVista® analysis is available on a secure web portal, enabling physicians to quickly diagnose and treat patients with suspected cardiovascular disease and answer important clinical questions. can lead to better treatment decisions. His CorVista system with CAD and PH add-ons is cleared by the FDA for sale in the United States. The CorVista System is developed and manufactured by Analytics For Life, Inc. and licensed to CorVista Health, Inc.

About CorVista Health

CorVista Health, Inc. is applying machine learning to deliver new heart disease detection algorithms using its proprietary CorVista System platform to transform cardiovascular care and the patient experience. CorVista Health is committed to providing access to actionable, high-quality cardiovascular results in low-resource settings where capital-intensive equipment and the qualified professionals needed to operate it are not available. , dedicated to achieving more equitable care. As such, the CorVista system is uniquely positioned to improve the quality of care in rural and low-resource settings.

For more information, please visit www.corvista.com.

View source version on businesswire.com. https://www.businesswire.com/news/home/20240404902310/ja/

contact address

grant smith
Phone: (317) 518-9807
info@analytics4life.com

[ad_2]

Source link